Zhimeng Biopharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
2ndary - Private
- Investors
-
16
Zhimeng Biopharma General Information
Description
Manufacturer of novel small-molecule therapeutics designed to treat chronic hepatitis B (CHB), liver diseases, and central nervous system (CNS) disorders. The company's platform utilizes medicinal chemistry, HBV capsid assembly modulation, toll-like receptor agonist development, and clinical trial execution, providing hepatology specialists, neurology centers, clinical researchers, and patients with small molecule drug candidates, HBV capsid modulators, and immune-modulating therapeutics to facilitate functional cure strategies for hepatitis B and treatments for neurological conditions.
Contact Information
Website
www.core-biopharma.comCorporate Office
- Building 32, Lane 388, Shengrong Road
- Pudong New Area
- Shanghai, 201210
- China
Corporate Office
- Building 32, Lane 388, Shengrong Road
- Pudong New Area
- Shanghai, 201210
- China
Zhimeng Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 11-Aug-2022 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 29-Oct-2021 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 03-Dec-2020 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series A) | 06-Nov-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 11-Nov-2019 | $14.2M | $14.2M | Completed | Generating Revenue | |
| 1. Early Stage VC | 05-Feb-2018 | Completed | Generating Revenue |
Zhimeng Biopharma Patents
Zhimeng Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025237304-A1 | Amide compound for treating and/or preventing hepatitis virus infections | Pending | 14-May-2024 | ||
| AU-2025217690-A1 | Crystal form of tetrahydroisoquinoline compound and use thereof | Pending | 08-Feb-2024 | ||
| WO-2025167886-A1 | Crystal form of tetrahydroisoquinoline compound and use thereof | Pending | 08-Feb-2024 | ||
| EP-4512804-A1 | Rho-associated protein kinase inhibitor and preparation and use thereof | Pending | 20-Apr-2022 | ||
| EP-4512804-A4 | Rho-associated protein kinase inhibitor and preparation and use thereof | Pending | 20-Apr-2022 | C07D403/14 |
Zhimeng Biopharma Signals
Zhimeng Biopharma Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advantech Capital Partners | PE/Buyout | Minority | ||
| Co-Stone Capital | PE/Buyout | Minority | ||
| Dawu Venture Capital | Venture Capital | Minority | ||
| DYEE Capital | Asset Manager | Minority | ||
| Fellow Partners | Venture Capital | Minority |
Zhimeng Biopharma FAQs
-
When was Zhimeng Biopharma founded?
Zhimeng Biopharma was founded in 2015.
-
Where is Zhimeng Biopharma headquartered?
Zhimeng Biopharma is headquartered in Shanghai, China.
-
What is the size of Zhimeng Biopharma?
Zhimeng Biopharma has 10 total employees.
-
What industry is Zhimeng Biopharma in?
Zhimeng Biopharma’s primary industry is Drug Discovery.
-
Is Zhimeng Biopharma a private or public company?
Zhimeng Biopharma is a Private company.
-
What is Zhimeng Biopharma’s current revenue?
The current revenue for Zhimeng Biopharma is .
-
How much funding has Zhimeng Biopharma raised over time?
Zhimeng Biopharma has raised $103M.
-
Who are Zhimeng Biopharma’s investors?
Advantech Capital Partners, Co-Stone Capital, Dawu Venture Capital, DYEE Capital, and Fellow Partners are 5 of 16 investors who have invested in Zhimeng Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process